Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.42 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.42 |
| ▸ | VHL | P40337 | 1/20 | 0.39 |
| ▸ | ELOC | Q15369 | 1/20 | 0.39 |
| ▸ | ELOB | Q15370 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2691734 | 0.80 | NPC1 (0.43) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL2940146 | 0.80 | MAPT (0.43) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL28195327 | 0.79 | METTL3 (0.42) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL28813192 | 0.78 | AKR1B1 (0.48) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL25515787 | 0.78 | ALOX15 (0.44) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL25515767 | 0.78 | ALOX15 (0.44) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL17372780 | 0.77 | SMN1; SMN2 (0.41) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL30401092 | 0.77 | TAAR1 (0.43) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL2945627 | 0.77 | NPC1 (0.41) | NPC1ALDH1A1POLBMAPTRAB9A | |
| SCHEMBL19682140 | 0.76 | ALDH1A1 (0.40) | NPC1ALDH1A1POLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6572664-B2 | Oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2003-06-03 | — | — | US | claimed |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | L'OREAL S.A. (FR) | 2002-11-21 | — | — | US | claimed |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | BRETON PHILIPPE (FR) | 2002-01-10 | — | — | US | claimed |
| EP-1129691-A2 | Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same | L'OREAL (FR) | 2001-09-05 | — | — | EP | claimed |
| WO-2023081306-A1 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | disclosed |
| EP-3157920-B1 | INDOLIZINE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-08-07 | — | — | EP | disclosed |
| EP-3157920-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2017-04-26 | — | — | EP | disclosed |
| US-9527869-B2 | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| US-9527869-B2 | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| US-9527869-B2 | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| WO-2015193263-A1 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-23 | — | — | WO | disclosed |
| US-7482337-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-27 | — | — | US | disclosed |
| EP-1562946-A1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2005-08-17 | — | — | EP | disclosed |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004041820-A1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-21 | — | — | WO | disclosed |
| US-6572664-B2 | Oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2003-06-03 | — | — | US | disclosed |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | L'OREAL S.A. (FR) | 2002-11-21 | — | — | US | disclosed |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | BRETON PHILIPPE (FR) | 2002-01-10 | — | — | US | disclosed |
| EP-1129691-A2 | Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same | L'OREAL (FR) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | NPC1 1980/4885ALDH1A1 198/4885POLB 2060/4885 |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | KRT18, INMT, IDO1 | NPC1 4832/4885ALDH1A1 897/4885POLB 833/4885 |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | KRT18, INMT, IDO1 | NPC1 4832/4885ALDH1A1 897/4885POLB 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.